Direkt zum Inhalt
Merck

A1349

Sigma-Aldrich

Monoclonal Anti-β-Amyloid (17-24) antibody produced in mouse

~1 mg/mL, clone 4G8, purified immunoglobulin, buffered aqueous solution

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

MDL-Nummer:
UNSPSC-Code:
12352203

Biologische Quelle

mouse

Konjugat

unconjugated

Antikörperform

purified immunoglobulin

Klon

4G8, monoclonal

Form

buffered aqueous solution

Speziesreaktivität

human

Konzentration

~1 mg/mL

Methode(n)

immunohistochemistry: 1:100-1:1000
immunoprecipitation (IP): 1:10-1:100
indirect ELISA: 1:103-1:105
western blot: 1:100-1:1000

Versandbedingung

dry ice

Lagertemp.

−20°C

Angaben zum Gen

human ... APP(351)

Immunogen

synthetic peptide corresponding to amino acids 17-24 of the human β amyloid peptide with Glu substituted at position 11, conjugated to KLH.

Physikalische Form

Solution in phosphate buffered saline.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Alina Hategan et al.
Nature structural & molecular biology, 24(4), 379-386 (2017-02-22)
Deposition of amyloid-β plaques is increased in the brains of HIV-infected individuals, and the HIV transactivator of transcription (Tat) protein affects amyloidogenesis through several indirect mechanisms. Here, we investigated direct interactions between Tat and amyloid-β peptide. Our in vitro studies
Jason H Y Yeung et al.
Frontiers in neuroscience, 13, 1427-1427 (2020-02-06)
Alzheimer's disease (AD) is the leading type of dementia worldwide. Despite an increasing burden of disease due to a rapidly aging population, there is still a lack of complete understanding of the precise pathological mechanisms which drive its progression. Glutamate
Congwei Wang et al.
Bio-protocol, 8(19), e3029-e3029 (2018-10-23)
Ribonucleoprotein particles (mRNPs) are complexes consisting of mRNAs and RNA-binding proteins (RBPs) which control mRNA transcription localization, turnover, and translation. Some mRNAs within the mRNPs have been shown to undergo degradation or storage. Those transcripts can lack general mRNA elements
M Medecigo et al.
Journal of neuroimmunology, 223(1-2), 104-114 (2010-05-11)
Anti-amyloid immunotherapy has been proposed as an appropriate therapeutic approach for Alzheimer's disease (AD). Significant efforts have been made towards the generation and assessment of antibody-based reagents capable of preventing and clearing amyloid aggregates as well as preventing their synaptotoxic
Stefania Zappettini et al.
Frontiers in pharmacology, 3, 146-146 (2012-08-07)
Using both in vitro (hippocampal synaptosomes in superfusion) and in vivo (microdialysis) approaches we investigated whether and to what extent β amyloid peptide 1-40 (Aβ 1-40) interferes with the cholinergic modulation of the release of glycine (GLY) in the rat

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.